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a b s t r a c t
Asylum seekers are a vulnerable population for contracting infectious diseases. Outbreaks occur among
children and adults. In the Netherlands, asylum seeker children are offered vaccination according to
the National Immunization Program. Little is known about protection against vaccine-preventable dis-
eases (VPD) in adult asylum seekers. In this 2016 study, we assessed the immunity of adult asylum seek-
ers against nine VPD to identify groups that might benefit from additional vaccinations. We invited
asylum seekers from Syria, Iran, Iraq, Afghanistan, Eritrea and Ethiopia to participate in a serosurvey.
Participants provided informed consent and a blood sample, and completed a questionnaire. We mea-
sured prevalence of protective antibodies to measles, mumps, rubella, varicella, diphtheria, tetanus, polio
type 1–3 and hepatitis A and B, stratified them by country of origin and age groups. The median age of the
622 participants was 28 years (interquartile range: 23–35), 81% were male and 48% originated from Syria.
Overall, seroprotection was 88% for measles (range between countries: 83–93%), 91% for mumps (81–
95%), 94% for rubella (84–98%), 96% for varicella (92–98%), 82% for diphtheria (65–88%), 98% for tetanus
(86–100%), 91% (88–94%) for polio type 1, 95% (90–98%) for polio type 2, 82% (76–86%) for polio type 3,
84% (54–100%) for hepatitis A and 27% for hepatitis B (anti-HBs; 8–42%). Our results indicate insufficient
protection against certain VPD in some subgroups. For all countries except Eritrea, measles seroprotec-
tion was below the 95% threshold required for elimination. Measles seroprevalence was lowest among
adults younger than 25 years. In comparison, seroprevalence in the Dutch general population was 96%
in 2006/07. The results of this study can help prioritizing vaccination of susceptible subgroups of adult
asylum seekers, in general and in outbreak situations.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
In recent years there has been a large influx of refugees in Eur-
ope. In several countries of origin, public health systems collapsed
and vaccination programmes have been interrupted due to war,
political or economic instability, resulting in inconsistent vaccina-
tion coverage among refugee populations [1]. In the EU, outbreaks
and isolated cases of several vaccine-preventable diseases (VPD),
such as measles [2], hepatitis A [3,4], varicella [5] and diphtheria
[6], have been reported among both children and adult refugees.
The World Health Organization recommends vaccination of
refugees, asylum seekers and migrants according to the host coun-
tries’ vaccination programme if they intend to stay in a country for
more than one week. Considering the outbreak potential, vaccina-
tion against measles, mumps and rubella (MMR), as well as polio
should be prioritized [7]. In the Netherlands, the vaccination status
of asylum seeker children and adolescents aged 0–18 years is eval-
uated within 6 weeks after arrival, and vaccinations are updated
according to the national immunization program (NIP) [8]. The
vaccination status of adult asylum seekers however is not routinely
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evaluated. Two recent serosurveys from Germany found that
immunity among adult asylum seekers was relatively high but
might still be insufficient to achieve herd immunity for measles,
mumps, rubella, varicella and diphtheria [9–11].
We conducted a seroprevalence survey in the Netherlands
among adult asylum seekers to determine the seroprevalence
against nine VPDs. By identifying immunity gaps and potential vac-
cination needs among adult asylum seekers, results of this study
can aid the development of vaccination policies for asylum seekers.
2. Materials & methods
2.1. Study design
In July and August 2016, we performed a cross sectional sero-
logical survey among adult asylum seekers living in three large
reception centres in The Netherlands.
2.2. Study population
Asylum seekers that met the following inclusion criteria were
eligible to participate in the study: (i) 18 to 45 years of age, (ii)
originating from Syria, Iran, Iraq, Afghanistan, Eritrea and Ethiopia,
and (iii) living in a reception centre in the Netherlands. We chose
this age range based on these reasons: insufficiently vaccinated
asylum seeker children below the age of 19 years are already
offered vaccination in the Netherlands and persons above the age
of 45 years are more likely to have protective antibody levels due
to natural infection [9]. Also, the majority of adult asylum seekers
housed in Dutch reception centres were younger than 45 years
(>80%) [12]. The countries we selected represented the countries
where most asylum seekers in The Netherlands originated from
in 2015 [13].
2.3. Participant recruitment
The Central Agency for the Reception of Asylum Seekers (COA)
is responsible for the reception of asylum seekers and offers hous-
ing during the (first) asylum procedure. In consultation with COA,
three reception centres were selected as study sites based on con-
venience regarding travel distance and size of the centre. These
three centres housed 1750 (8%) asylum seekers of the 22,000
asylum seekers present in the Netherlands who met the inclusion
criteria (personal communication COA, data as on 1-2-2016). One
week prior to data collection, eligible participants received an invi-
tation letter in Arabic, Farsi, Tigrinya, Amharic, Dutch or English. A
flyer with icons describing the study graphically was included to
also reach illiterate asylum seekers. Posters with information about
the study were placed in the communal areas. In addition, person-
nel from the centres orally informed eligible study participants.
2.4. Data collection
Two to four consecutive sampling days were held at each centre
in July and August 2016. On these sampling days, interpreters (Ara-
bic, Farsi, Tigrinya and Amharic) explained the study aim and proce-
dures to eligible persons, and assisted with filling in the informed
consent form and the questionnaire. The questionnaire contained
questions about demographics (sex, age, country of birth, educa-
tional level according to the UNESCO International Standard Classi-
fication of Education), and whether the person grew up in an urban
or rural environment. Also, participants were asked whether they
had received vaccinations as a child, andwhether theywould accept
any future vaccination if indicated and offered to them in the
Netherlands. To prevent potentially lower participation of women
due to cultural reasons, we specifically recruited female nurses to
collect a blood sample from all participants (8.5 mL, BD Vacutainer
SSTTM II Advance tubes). All datawere processed anonymously: the
questionnaire and blood sample were labelled with a unique study
number and no person identifiable information was collected.
2.5. Serological analysis
After sample collection, blood samples were kept at room tem-
perature. Upon transfer to the National Institute for Public Health
and the Environment at the end of the sampling day, samples were
stored in the refrigerator until further processing the next morn-
ing. After centrifugation, serum aliquots were filled out and were
stored at 20 C.
IgG antibodies against measles-, mumps-, rubella- and varicella
virus, and diphtheria and tetanus were determined using fluores-
cent bead-based multiplex immunoassay (Luminex xMAP technol-
ogy), as described before [14,15]. In all assays a reference, controls
and blanks were included on each plate. All analysis was per-
formed with a Bio-Plex 200 in combination with Bio-Plex manager
software (Bio-Rad Laboratories, Hercules, CA).
Hepatitis A and hepatitis B (markers: anti-HBc, HBsAg, anti-
HBs) serology was performed using chemoluminescence assays
performed on the ADVIA Centaur XP assay system (Siemens HBsA-
gII assay, HBcT, aHBs2, AHAVT). A positive test result for HBsAg
was confirmed by a neutralisation assay (Siemens) and/or by PCR
(COBAS Taqman, Roche).
Poliovirus neutralising antibody titres against serotypes 1, 2,
and 3 were determined by the neutralisation test (NT) using Sabin
vaccine strains, as recommended by the WHO [16].
Participants were considered protected when IgG concentra-
tions were above or equal to the following disease-specific cut offs:
0.20 IU/mL for measles, 45 IU/mL for mumps, 10.0 IU/mL for
rubella, 0.26 IU/mL for varicella, 0.01 IU/mL for diphtheria,
0.01 IU/mL for tetanus, 20 mIU/mL for hepatitis A and >10
mIU/mL for hepatitis B (anti-HBs). For hepatitis B, vaccine-
induced immunity is defined as anti-HBs positivity without other
markers. Anti-HBc-, in combination with anti-HBs-positivity indi-
cates a resolved infection with immunity, while anti-HBc positivity
with presence of HBsAg indicates a chronic infection. For poliovirus
NT titres 8 were considered protective. For diphtheria and teta-
nus protective immunity was further subdivided into basic protec-
tion (0.01–0.099 IU/mL) and full protection (0.1 IU/mL).
Hereafter, we refer to seroprevalence of protective antibody levels
as seroprevalence.
2.6. Statistical analyses
Serological results for measles, mumps, rubella and varicella
were available for all study participants (n = 622). For diphtheria,
tetanus, and hepatitis A, seroprevalence results were available for
620 participants and for hepatitis B for 617 participants, respec-
tively. Due to limited resources, we only tested a subset of samples
(n = 300, 48%) for the presence of antibodies against polio virus
types 1–3. We used SPSS (IBM Corp, version 24) to determine the
subset of samples, that constituted of a random selection of 100
sera from Syrian participants (as this was the largest group), and
50 sera each from participants from other eligible countries.
We calculated seroprevalences, determined exact 95% confi-
dence intervals (Clopper Pearson) and stratified seroprevalence
between gender, age groups (18–25, 26–35, 36–45) and country
of birth using Chi square tests or Fisher’s exact tests. For the com-
parisons of seroprevalence between countries of birth, we
excluded participants from Ethiopia due to the low sample size
(n = 2). To investigate trends in seroprevalence between age
groups, we used the Cochrane Armitage Trend test. We tested
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whether observed seroprevalence for measles, mumps, rubella,
varicella, diphtheria and polio were statistically significantly below
established herd immunity thresholds by using one-tailed one-
sample z-tests for proportion. For measles and rubella, we used
the WHO threshold of 95% required for measles and rubella elimi-
nation [17]. We used the upper limits of the herd immunity thresh-
olds determined by Plans Rubio et al., for varicella (91%), mumps
(93%), diphtheria (80%) and polio (86%) as thresholds for sero-
prevalence. [18]. Subgroups within the study population were con-
sidered insufficiently protected when their age- and country-
specific seroprevalence was significantly below these thresholds.
A p-value (P) of 0.05 was considered statistically significant.
Data analysis was conducted in Stata (StataCorp LP, Texas, USA,
version 14.2). Figures were made in RStudio (R studio Inc., Boston,
MA, USA, version 0.99.903) using the package ‘ggplot2’.
2.7. Ethics
This study was approved by the Medical Ethical Committee
Noord-Holland (number: M016-010/ NL56277.094.16). Potential
participants were informed that their asylum procedure would
not be influenced by (non)participation or by the test results, and
that participants would not receive their test results. All partici-
pants provided written informed consent. Data collection and anal-
ysis was anonymous.
3. Results
In total, 637 adult asylum seekers participated in the study. Fif-
teen participants were excluded from the final analysis: 10 partic-
ipants did not meet the inclusion criteria (two fell outside the
defined age range and eight originated from countries other than
those specified) and from five participants no blood sample could
be taken.
The final study population comprised of 622 participants: 297
were from Syria, 109 from Iran, 83 from Iraq, 75 from Afghanistan,
56 from Eritrea and 2 from Ethiopia, respectively. Table 1 shows
the characteristics of the study population. The median age of all
study participants was 28 years (IQR: 23–35) and 81% were male
(Table 1). Ages were comparable between men (median: 28, IQR:
23–35) and women (median: 29, IQR: 25–35 (p = 0.301). Of the
622 participants, 552 (89.5%) reported having a positive attitude
towards future vaccinations, 20 were opposed (3.2%) and 45 did
not know (7.3%). Five participants did not answer the question.
3.1. Seroprevalence
Country-specific seroprevalence including 95% CI are depicted
in Fig. 1. Seroprevalence by country and age group are shown in
Fig. 2. In Table 2, we provided detailed information about sero-
prevalence stratified by country and age groups, and results from
significance testing. We found no significant differences between
males and females for measles, mumps, rubella, varicella, tetanus,
polio types 1–3 and hepatitis A. Gender differences were only
found for diphtheria and hepatitis B.
3.1.1. Measles
Country-specific measles seroprevalence was statistically sig-
nificantly below the 95% herd immunity threshold for all countries
except Eritrea. The lowest seroprevalence was observed for partic-
ipants from Iran: overall 83.5% and for those aged 18–25 years
(70%).
3.1.2. Mumps
Mumps seroprevalence ranged from 81% (Iraq) to 95.4% (Iran).
All countries were above or equal to the immunity threshold of
93% for mumps, except for participants from Iraq. Age-specific
seroprevalence was insufficient for Syrian participants aged 18–
25 years and Iraqi participants older than >25 years.
3.1.3. Rubella
The overall rubella seroprevalence was above or comparable to
the 95% threshold for participants from all countries, except for
Iraq (84%). Stratified by age group, only three subgroups were
below the threshold: those aged 18–25 from Iraq (88%, borderline
significant), and those aged 26–35 years from Syria (89.4%) and
Iraq (80%), respectively.
3.1.4. Varicella
Varicella seroprevalence was above the threshold of 91% for all
countries and ranged from 91.7% for Iran to 98% for participants for
Iraq, respectively. None of the age-group specific seroprevalences
were below the threshold.
3.1.5. Diphtheria
Diphtheria seroprevalence ranged from 65% for Afghan partici-
pants to 88.1% for Iranian participants. Only the seroprevalence for
participants from Afghanistan was below the established immu-
nity threshold of 80%. Diphtheria seroprevalence was higher in
men (83%) than women (75%; P = 0.037). Basic and full protection
levels differed significantly between countries (p-value < 0.001).
The proportion of participants with full protection was highest
for Iran (62%) and lowest for Afghanistan (27%) and Iraq (28%),
respectively (Fig. 3a).
3.1.6. Tetanus
The tetanus seroprevalence was high for all countries (96% to
100.0%) except for participants from Eritrea (86%). The lowest teta-
nus seroprevalence was observed in Eritreans aged 36–45 years
(79%). Countries differed significantly regarding the level of full
and basic protection (p-value < 0.001). The level of full protection
Table 1
Characteristics of adult asylum seekers that participated in the serosurvey (n = 622),
The Netherlands, July–August 2016
Characteristic n %
Gender Male 504 81.0
Female 117 18.8
Missing 1 0.2
Age group 18–25 203 32.6
26–35 274 44.1
36–45 145 23.3
Country of birth Syria 297 47.8
Iran 109 17.5
Iraq 83 13
Afghanistan 75 12
Eritrea 56 9
Ethiopia 2 0.3
Environment grow up Rural 106 17
Urban 505 81.2
Missing 11 2
Highest level of education Primary school 188 30.2
Secondary school 216 34.7
Intermediate 67 11
University/college 145 23.5
Missing 5 1
Self-reported childhood vaccinations Yes 526 84.6
No 15 2
Do not know 74 12
Missing 7 1
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was highest for participants from Iran (96%) and lowest for Eritrea
(41%; Fig. 3b).
3.1.7. Polio
For all three poliovirus types, seroprevalencedid not differ signif-
icantly between countries, and ranged from 88 to 94% for polio type
1, 90–98% for polio type 2 and 76–86% for polio type 3, respectively.
With exception of polio type 3 for Iraq (76%, P = 0.020) and – border-
line – for Eritrea (78%, P = 0.052), polio seroprevalence in all other
countries was not significantly below the herd immunity threshold
of 86% for all polio types. Stratifiedby age group, only two subgroups
were below the threshold: 26–35-year-olds from Iraq (63% polio
type 3, P = 0.003) and Eritrea (71% polio type 3, P = 0.027).
3.1.8. Hepatitis A
Hepatitis A seroprevalence differed significantly between coun-
tries (p-value < 0.001). The seroprevalence of hepatitis A was low-
est for participants from Iran (53.7%). For the other countries it
ranged from 85% (Syria) to 100% (Eritrea). Hepatitis A seropreva-
lence significantly increased with age for participants from Syria
(75% in 18–25 years to 96% in 36–45 years, p-value < 0.001) and
Iran (from 42–44% in 18 to 35 years to 91% in 36–45 years, p-val
ue = 0.001).
3.1.9. Hepatitis B
Vaccine induced immunity for hepatitis B ranged from 4.8% for
participants from Iraq to 34.3% for participants from Iran. Women
(29.8%) more often had vaccine induced antibody levels than men
(17.7%, p = 0.004). Syrian participants aged 18–25 years, Iranians
aged 18–35 years and Afghans aged 36–45 had the highest preva-
lence of immunity through vaccination (36–39%, Fig. 4). Markers
indicating resolved or chronic infection (anti-HBc) were most often
present in participants from Eritrea (25%) and least often in partic-
ipants from Iran (4.6%). Anti-HBc prevalence increased with age
with the exception of participants from Afghanistan, where 9 of
36 participants (25%) in the 18–25 year age group had markers
indicating a natural infection. Seven participants had a chronic
HBV infection (HBsAg): of these, three were from Eritrea (6%), three
from Syria (1.0%), and one from Afghanistan (1%).
3.2. Self reported childhood vaccination
In total, 526/615 participants (84.6%) indicated they had
received childhood vaccinations, 74 (11.9%) did not know and 15
(2.4%) indicated they were not vaccinated as a child. Measles pro-
tection was comparable between these three groups: 87.6%, 89.2%
and 86.7% for ‘vaccinated’, ‘don’t know’ and ‘not vaccinated’,
respectively (P = 0.921). For tetanus, these percentages were differ-
ent between the groups: 82.9%, 66.2% and 53.5% for ‘vaccinated’,
‘don’t know’ and ‘not vaccinated’, respectively (P < 0.001).
4. Discussion
This study showed that in 2016 the overall seroprevalence for
mumps, rubella, varicella, diphtheria, tetanus, polio and hepatitis
A was generally high among adult asylum seekers in the Nether-
lands. However, measles seroprevalence was below the herd
immunity threshold for all but one country of origin. Measles sero-
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Fig. 1. Disease-specific seroprevalence including exact 95% confidence intervals by country of origin.
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prevalence was lowest among adults younger than 25 years. This is
likely due to suboptimal vaccination coverage combined with
decreased circulation of measles virus. Our study population was
born between 1970 and 1998. In the 1980s, based on data reported
to the WHO, vaccination coverage for ‘measles containing vaccine’
was low, and ranged from 10% for Syria, Afghanistan and Ethiopia
(which included Eritrea at the time before its independence in
1993) to 40% for Iran and Iraq. In the 1990s, reported measles
vaccination coverage increased to 90% for Syria and 95% for Iran
and Iraq, respectively, whereas coverage remained low for Afghani-
stan, Eritrea and Ethiopia (range: 30–40%) [19].
Our findings for measles, rubella and varicella are largely in line
with those reported in recent studies from Germany [9,10].
Although age groups were not directly comparable between our
study and that of Toikkanen et al. [9], both studies showed that
the seroprevalence against measles was relatively low in young
adults from Iran, Iraq, Syria and Afghanistan. For rubella, immunity
was below the 95% threshold for 26–35 year old asylum seekers
from Syria and Iraq, which was similar to findings by Toikkanen
and colleagues [9]. In contrast, full immunity for diphtheria and
tetanus was lower in asylum seekers tested in Germany compared
to this study, with seroprevalences of 23.9% versus 38.6% for diph-
theria and 43.7% versus 80.2% for tetanus, respectively [11]. In the
former study, seroprevalence was not stratified by country of ori-
gin, hence it was not possible to further compare these differences.
The conclusions of our and the German studies are based on
humoral immunity outcome (antibodies), however, in addition
also cellular immunity contributes to immunity against infectious
diseases. This implies that overall protection against vaccine pre-
ventable diseases could be under-estimated.
As the interpretation and potential implications of our findings
regarding the risk of adult asylum seekers to contract VPD largely
depend on the context in which adult asylum seekers reside in, as
well as the level of social or geographical clustering, we discuss dif-
ferent contexts separately in the sections hereafter:
In countries with high vaccination coverage, such as The
Netherlands, adult asylum seekers who are not sufficiently pro-
tected are likely to be protected by herd immunity. Levels of
immunity for measles, mumps, rubella, diphtheria and polio, are
high in the general Dutch population [20–23]. Refugees with a res-
ident status are usually housed throughout the country and will
therefore be geographically distributed over the country, although
social clustering of susceptible refugees may occur. Even though
our study shows that asylum seekers are generally adequately pro-
tected, susceptible asylum seekers can potentially be exposed to
certain VPDs. For instance, varicella is not included in the Dutch
NIP and is highly endemic among toddlers. The Netherlands has
experienced outbreaks of measles, mumps and rubella in the past
decade [24–26]. These outbreaks were largely confined to ortho-
dox Protestants, who often refuse vaccination on religious grounds
(vaccination coverage in these communities is 60%) and who live
in socially and geographically clustered communities; the so-called
‘Bible Belt’ [26]. Mumps outbreaks have also occurred among stu-
dents who are at risk of infection due to waning vaccine-induced
immunity and social clustering [27]. We consider the risk of adult
asylum seekers to contract mumps in the Netherlands to be low, as
the high immunity in the asylum seeker population is likely
acquired through natural infection, resulting in a stronger immune
response compared to vaccination. Mumps vaccination was gener-
ally not yet included in the national immunisation programs in the
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Fig. 2. Disease-specific seroprevalence including exact 95% confidence intervals by country of origin and age groups.
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Table 2
Total number of adult asylum seekers (total n), disease-specific seroprotection levels (%) and exact 95% confidence intervals (95% CI) by country of birth and age group in years,
The Netherlands, July–August 2016.
Country of birth: Syria Iran Iraq Afghanistan Eritrea Total n
Disease Age group Total n % 95% CI Total n % 95% CI Total n % 95% CI Total n % 95% CI Total n % 95% CI
Measles a 18–25 91 87 78–93 33 70 51–84 25 80 59–93 36 83 67–94 18 94 73–100 203
26–35 123 86.2 78.8–91.7 53 91 79–97 44 93 81–99 28 93 77–99 24 88 68–97 272
36–45 83 93 85–97 23 87 66–97 14 93 66–100 11 91 59–100 14 100 77–100b 145
Total 297 88.2 84.0–91.7 109 83.5 75.1–89.9 83 89 80–95 75 88 78–94 56 93 83–98 620
Mumps a 18–25 91 88 79–94 33 94 80–99 25 88 62–89 36 94 81–99 18 94 73–100 203
26–35 123 91.9 85.6–96.0 53 94 84–99 44 77 49–95 28 89 72–98 24 88 68–97 272
36–45 83 99 94–100b 23 100 85–100b 14 79 49–95 11 91 59–100 14 93 66–100 145
Total 297 92.6 89.0–95.2 109 95.4 89.6–98.5 83 81 71–89 75 92 83–97 56 91 80–97 620
Rubella a 18–25 91 98 92–100 33 100 89–100b 25 88c 69–98 36 94 81–99 18 100 82–100b 203
26–35 123 89.4 82.6–94.3 53 100 93–100b 44 80 65–90 28 96 82–100 24 100 86–100b 272
36–45 83 95 88–99 23 91 72–99 14 93 66–100 11 100 72–100b 14 93 66–100 145
Total 297 93.6 90.2–96.1 109 98.2 93.5–99.8 83 84 75–91 75 96 89–99 56 98 90–100b 620
Varicella a 18–25 91 93 86–98 33 91 76–98 25 96 80–100 36 97 86–100 18 100 82–100b 203
26–35 123 98.4 94.3–99.8 53 91 79–97 44 98 88–100 28 96 82–100 24 88 68–97 272
36–45 83 99 94–100b 23 96 78–100 14 100 77–100b 11 91 59–100 14 100 77–100b 145
Total 297 97.0 94.3–98.6 109 91.7 84.9–96.1 83 98 92–100 75 96 89–99 56 95 85–99 620
Diphtheria a 18–25 91 91 83–96 33 85 68–95 25 80 59–93 36 72 55–86 17 88 64–99 202
26–35 123 79.7 71.5–86.4 53 94 84–99 44 75 60–87 28 57 37–76 23 78 56–93 271
36–45 83 80 69–88 23 78 56–93 14 93 66–100 11 64 31–89 14 100 77–100b 145
Total 297 83.2 78.4–87.2 109 88.1 80.5–93.4 83 80 69–88 75 65 54–76 54 87 75–95 618
Tetanus 18–25 91 100.0 96–100b 33 100 89–100b 25 100 86–100b 36 94 81–99 17 89 65–99 202
26–35 123 99.2 95.6–100b 53 100 93–100b 44 100 92–100b 28 96 82–100 23 88 68–97 271
36–45 83 98 92–100 23 100 85–100b 14 100 77–100b 11 100 72–100b 14 79 49–95 145
Total 297 99.0 97.1–99.8 109 100 96.7–100b 83 100 96–100b 75 96 89–99 54 86 74–94 618
Polio type 1a 18–25 32 97 84–100 18 100 82–100b 13 77 46–95 30 97 83–100 16 100 79–100b 109
26–35 36 94 81–99 19 84 60–97 27 93 76–99 14 79 49–95 21 81 58–95 117
36–45 32 91 75–98 13 77 46–95 10 100 69–100b 6 100 54– 100b 13 92 64–100 74
Total 100 94.0 87.4–97.8 50 88 76–96 50 90 78–97 50 92 81–98 50 90 78–97 300
Polio type 2a 18–25 32 94 79–99 18 94 73–100 13 85 55–98 30 97 83–100 16 100 79– 100b 109
26–35 36 100 90–100b 19 95 74–100 27 93 76–99 14 86 57–98 21 95 76–100 117
36–45 32 97 84–100 13 85 55–98 10 90 56–100 6 100 54–100b 13 100 75–100b 74
Total 100 97.0 91.5–99.4 50 92 81–98 50 90 78–97 50 94 84–99 50 98 89–100 300
Polio type 3a 18–25 32 88 71–97 18 89 65–99 13 92 64–100 30 87 69–96 16 88 62–98 109
26–35 36 86 71–95 19 74 49–91 27 63 42–81 14 86 57–98 21 71 48–89 117
36–45 32 84 67–95 13 77 46–95 10 90 56–100 6 83 36–100 13 80 46–95 74
Total 100 86.0 77.6–92.1 50 80 66–90 50 76 62–87 50 86 73–94 50 78c 64–89 300
Hepatitis A 18–25 91 75 65–83 33 42 26–61 25 92 74–99 36 100 90–100b 18 100 82–100b 203
26–35 123 86.2 78.8–91.7 52 44 31–59 44 96 85–99 27 96 81–100 24 100 86–100b 270
36–45 83 96 90–99 23 91 72–99 14 100 77–100b 11 100 72–100b 14 100 77–100b 145
Total 297 85.5 81.0–89.3 108 53.7 43.8–63.3 83 95 88–99 74 99 93–100b 56 100 94–100b 618
Hepatitis B (anti-HBs) 18–25 91 39 28–49 33 42 26–61 25 12 3–31 36 44 28–62 17 6 0.1–29 202
26–35 123 18.7 12.2–26.7 52 40 27–55 44 7 1–19 27 30 14–50 22 32 14–55 268
36–45 83 23 14–33 23 22 8–44 14 7 0.2–34 11 64 31–89 14 21 5–51 145
Total 297 25.9 21.0–31.3 108 37.0 28–47 83 8 4–17 74 42 31–54 53 21 11–34 615
a Seroprotection levels depicted in bold face indicate that the level of protection in the respective subgroup was significantly lower compared to the respective disease-
specific herd immunity threshold (p-value < 0.05): Significance testing was conducted using an one-sided z-test comparing observed seroprotection levels against the herd
immunity threshold of 95% for measles and rubella [17], or against the upper limits of established threshold for immunity for varicella (91%), mumps (93%), diphtheria (80%)
and polio (86%), as described here [18].
b One-sided, 97.5% confidence interval.
c Borderline significant (p-value-range = 0.052–0.054).
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Fig. 3. Seroprevalence of (a) diphtheria and (b) tetanus stratified by basic and full seroprotection levels.
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countries of origin of our study population. Diphtheria, tetanus and
polio are extremely rare in the Netherlands.
In a wider European and global context it is important to take
the epidemiological situation into account, regarding risk of expo-
sure and susceptibility of refugees, for instance during their flight.
Over the recent months, the number of measles notifications has
been increasing in Europe, especially in Southern and South-
Eastern Europe [28]. This means susceptible refugees could be at
risk of measles exposure in parts of Europe. With regard to the glo-
bal polio eradication initiative it is reassuring that the seropreva-
lence of antibodies against polio among adult asylum seekers was
generally high in our study. However, the current outbreak of
vaccine-derived polio type 2 in Syria stresses the importance of
maintaining a high vaccination coverage [29]. Compared to our
findings, a study among asylum seekers in the United States
reported lower seroprevalences, with 80.5% for type 1, 87% for type
2 and 71.1% for type 3. Similar to our results, seroprevalence was
lower against type 3 compared to types 1 and 2 [30]. An Italian study
reported particularly high seroprevalence against all three polio
types among mainly African asylum seekers (99.5–99.8%) [31].
Crowded asylum seeker accommodations constitute vulnera-
ble settings for outbreaks, in particular for measles. Although
measles outbreaks have not occurred in reception centres in the
Netherlands, an outbreak did occur in a refugee settlement compa-
rable to a shanty town in France in 2016, where the likely index
case was identified to be a volunteer [2]. The seroprevalence for
hepatitis A in the general Dutch population is 39%, with the suscep-
tible population becoming younger [32]. Hepatitis A transmission
in the Netherlands is relatively rare, although an outbreak among
men who have sex with men is currently ongoing [33]. Immunity
against hepatitis A is higher in asylum seekers (84%), compared
to the general Dutch population, but outbreaks of hepatitis A in
asylum seeker settings have been described [3,4]. Our findings
can support discussions until what age hepatitis A vaccinations
should be offered to asylum seekers in case of an outbreak in a
reception centre. Diphtheria cases among refugees in Europe have
occurred in recent years, suggesting potential occasional diphthe-
ria transmission in refugee camp settings [6]. Our study showed
that diphtheria seroprevalence was lowest among adults from
Afghanistan. However, exposure in the Netherlands is unlikely, as
the diphtheria seroprevalence in is high (91%) [34].
Regarding the implications of our findings for individuals,
rubella, varicella, tetanus and hepatitis B immunity are of particu-
lar interest. Rubella and varicella immunity was high among adult
asylum seekers and did not differ between sexes. Varicella vaccina-
tion is not included in the Dutch National Immunisation Pro-
gramme. Whereas the mean age of infection in the Netherlands
is relatively low and >95% of children are immune by the age of
six [35], the risk of varicella complications increases with age
and varicella infection during pregnancy or shortly after birth
can cause severe disability in the new-born [36]. These conse-
quences emphasise the importance of sufficiently high immunity
levels against varicella. In the Netherlands pregnant asylum seek-
ers are screened for rubella and varicella [37]. Given the high sero-
prevalence of 94% for varicella and 92% for rubella among female
participants in this study, one could question the need for routine
screening of pregnant women. However, exposure to varicella is
likely due to high circulation in the Netherlands and, although
rubella is not endemic in the Netherlands, outbreaks in the Bible
Belt region occur occasionally. Furthermore, our study only
included 117 women from five countries, hence representativeness
and extrapolation to the wider group of pregnant asylum seekers
may be limited.
Tetanus immunity was high (>90%) for most subgroups, except
for study participants from Eritrea (80%). This is similar to the
Dutch population, where tetanus seroprevalence is 91%. [11].
According to WHO immunization coverage data, diphtheria and
tetanus vaccination coverage has been around 20% in the 1980 s
and 1990s in Afghanistan [19]. This may explain our findings
regarding diphtheria, but does not align with the high tetanus
seroprevalence for this subgroup. As antibodies against tetanus
can only be acquired through vaccination, the high seroprevalance
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in our study population suggest a higher vaccination coverage. Pos-
sibly, tetanus vaccination could have been received in adulthood,
e.g. after an accident or during military service. This may also
explain our finding that 53% of those who reported not to be vac-
cinated as a child, had tetanus immunity.
Vaccine-induced immunity against hepatitis B virus (HBV) dif-
fered by country and was 5–6% in participants from Eritrea and
Iraq, and 20–34% in participants from Syria, Afghanistan and Iran.
The higher prevalence of vaccine-induced immunity in women
might be related to vaccination in the context of antenatal care.
Overall hepatitis B immunity, including immunity through natural
infection was lowest in participants from Iraq (8%) and highest in
those from Afghanistan (42%). The incidence of acute HBV infection
in the Netherlands is very low (0.6 per 100,000 population) [38],
which points to a low risk of acquiring HBV and therefore does
not indicate additional vaccination needs. However, the relatively
high prevalence of chronic infection, especially among Eritreans,
supports the recent recommendation of the Dutch Health Council
to offer screening for chronic HBV infection to migrants from inter-
mediate or high-endemic countries [39].
This study had several limitations. Firstly, as we only recruited
asylum seekers from countries that accounted for the majority of
the asylum seeker population in The Netherlands and Europe in
2015, the findings of this study cannot be extrapolated to the gen-
eral adult asylum seeker population. As of June 2017, the distribu-
tion of countries of origin is similar to that of 2015 [12]. However,
this might change in the future. Secondly, the subgroup analysis
was performed on relatively small groups of asylum seekers,
resulting in wide confidence intervals. Thirdly, the majority of par-
ticipants in our study were male (81%). This can mostly be
explained by the gender imbalance in reception centres in the
Netherlands where the majority is male (i.e. 72% at the time of
the study). However, we do not believe that the overrepresentation
of men has influenced our results, as there were no differences in
seroprevalence between men and women for most VPDs.
A strength of this study is that nine VPDs were investigated. As
we reported serological results by country of birth and age group,
our study provides detailed information on immunity against VPDs
among adult asylum seekers. In particular for polio, immunity in
refugees in Europe has not been recently described.
In line with previous evidence, results from our study suggest
that universal vaccination of adult asylum seekers may not be nec-
essary, considering the overall adequate levels of seroprotection in
this population. However, given the immunity gaps in subgroups of
adult asylum seekers for measles, offering measles vaccination to,
e.g. the youngest adults (i.e. those born after 1990) could be con-
sidered, in line with ECDC and WHO which recommend to offer
vaccinations according to the national vaccination program of the
respective host country [1,7]. Ensuring high levels of protection
against measles is of utmost importance in the progress towards
elimination of measles [17], which is threatened by current out-
breaks in Europe [28].
In conclusion, this study raises some concerns for measles
immunity among subgroups of adult asylum seekers, especially
those coming from Syria, Iran, Iraq and Afghanistan. These findings
can be valuable in the context of discussions concerning vaccina-
tion and public health policies for migrants in Europe.
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